TerriConneran (@terriconneran) 's Twitter Profile
TerriConneran

@terriconneran

T like Trouble @KRASKickers
Too spunky for #LungCancer
Kicking cancer’s #KRAS #research #advocate #survivor
#hope ❤️🤣🙏#biomarker
NO #KRASholes

ID: 1330538180240691202

linkhttp://www.KRASKickers.org calendar_today22-11-2020 15:49:22

2,2K Tweet

1,1K Followers

888 Following

Cancer Discovery (@cd_aacr) 's Twitter Profile Photo

Congratulations to Sandra Misale, PhD, recipient of the 2025 Cancer Discovery Early Career Award, which recognizes the outstanding contributions of #earlycareer investigators. Learn more: brnw.ch/21wSfdp #AACR25 Johns Hopkins Medicine Johns Hopkins Kimmel Cancer Center AACR

Congratulations to <a href="/Sandra_Misale/">Sandra Misale</a>, PhD, recipient of the 2025 Cancer Discovery Early Career Award, which recognizes the outstanding contributions of #earlycareer investigators. Learn more: brnw.ch/21wSfdp
#AACR25 <a href="/HopkinsMedicine/">Johns Hopkins Medicine</a> <a href="/hopkinskimmel/">Johns Hopkins Kimmel Cancer Center</a> <a href="/AACR/">AACR</a>
Jill Feldman (@jillfeldman4) 's Twitter Profile Photo

Dr Shokat talk at opening plenary at #AACR25 on how progress in studying #KRAS, historically known as ‘undruggable’, led to developing drugs to target it. Never say never… The impossible CAN be possible! KRASKickers #LCSM

Dr Shokat talk at opening plenary at #AACR25 on how progress in studying #KRAS, historically known as ‘undruggable’, led to developing drugs to target it. Never say never…
The impossible CAN be possible! 
<a href="/KRASKickers/">KRASKickers</a> #LCSM
A.n.n. (@fireflyann) 's Twitter Profile Photo

#AACR25 session today ND01 - AMG 410: An H/NRAS-sparing pan-KRAS inhibitor with dual GTP(on)/GDP(off)-state activity for the treatment of diverse KRAS-mutant tumors A FIH study with AMG 410 is planned CRC, PDAC, NSCLC) G12D, G12V, G13D abstractsonline.com/pp8/#!/20273/p… KRASKickers

#AACR25 session today

ND01 - AMG 410: An H/NRAS-sparing pan-KRAS inhibitor with dual GTP(on)/GDP(off)-state activity for the treatment of diverse KRAS-mutant tumors 

A FIH  study with AMG 410 is planned CRC, PDAC, NSCLC) 

G12D, G12V, G13D
abstractsonline.com/pp8/#!/20273/p…
<a href="/KRASKickers/">KRASKickers</a>
A.n.n. (@fireflyann) 's Twitter Profile Photo

conclusion slide many slides of interest including KRAS targets & their responses as well as combinatorial options (EGFRi & anti-PD-1) KRASKickers #AACR25

conclusion slide 

many slides of interest including KRAS targets &amp; their responses as well as combinatorial options (EGFRi &amp; anti-PD-1)  

<a href="/KRASKickers/">KRASKickers</a>     #AACR25
Abner Antonio Murray, MD PhD (@dominicandoc2) 's Twitter Profile Photo

Christine Lovly, MD, PhD, FASCO AACR IASLC Very exciting early signals for JYP0322 at #AACR25 — especially promising that no DLTs were observed and MTD wasn't reached during dose escalation. Also interesting that patients with stable CNS metastases were eligible — curious to see more on intracranial outcomes as data

A.n.n. (@fireflyann) 's Twitter Profile Photo

SY08 - Developments in RAS Signaling Inhibition: Bench to Bedside Frank McCormick! Piro Lito! Sandra Misale! abstractsonline.com/pp8/#!/20273/s… KRASKickers Sandra Misale

SY08 - 
Developments in RAS Signaling Inhibition: Bench to Bedside 

Frank McCormick!
Piro Lito!
Sandra Misale! 

abstractsonline.com/pp8/#!/20273/s…

<a href="/KRASKickers/">KRASKickers</a> <a href="/Sandra_Misale/">Sandra Misale</a>
Cancer Discovery (@cd_aacr) 's Twitter Profile Photo

Online now concurrent with the #AACR25 oral presentation by Cancer Discovery Early Career Award Winner Sandra Misale: Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations brnw.ch/21wSh8j

Online now concurrent with the #AACR25 oral presentation by Cancer Discovery Early Career Award Winner <a href="/Sandra_Misale/">Sandra Misale</a>: Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations brnw.ch/21wSh8j
Balazs Halmos (@balazshalmosmd) 's Twitter Profile Photo

Big Ben of thoracic oncology teaches us after recent failures how to make ADCs great again! Upfront combinations of Dato-dxd w pembro+_ platinum in TROPION Lung02 seem feasible although some AE concerns- activity enriched by NMR QCS and might be the way forward to enrich patient

Daniel Gerlach (@gerlach_d) 's Twitter Profile Photo

BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction | Science science.org/doi/10.1126/sc…